MCID: PYD001
MIFTS: 54

Pyoderma Gangrenosum

Categories: Bone diseases, Rare diseases, Skin diseases

Aliases & Classifications for Pyoderma Gangrenosum

MalaCards integrated aliases for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 12 74 52 58 54 43 15 17 71 32

Characteristics:

Orphanet epidemiological data:

58
pyoderma gangrenosum
Prevalence: 1-9/100000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8553
ICD9CM 34 686.01
MeSH 43 D017511
SNOMED-CT 67 74578003
ICD10 32 L88
MESH via Orphanet 44 D017511
ICD10 via Orphanet 33 L88
UMLS via Orphanet 72 C0085652
Orphanet 58 ORPHA48104
UMLS 71 C0085652

Summaries for Pyoderma Gangrenosum

NIH Rare Diseases : 52 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis , Crohn's disease , polyarthritis (an inflammation of several joints together), gammopathy , vasculitis, leukemia, and other conditions. Each year in the United States, pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses . Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy. Treatment involves wound care and the use of anti-inflammatory agents, including antibiotics , corticosteroids , immunosuppressants, and biologics.

MalaCards based summary : Pyoderma Gangrenosum is related to crohn's disease and colitis. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Minocycline and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and breast, and related phenotypes are fever and arthralgia

Wikipedia : 74 Pyoderma gangrenosum is a rare, inflammatory skin disease where painful pustules or nodules become... more...

Related Diseases for Pyoderma Gangrenosum

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 645)
# Related Disease Score Top Affiliating Genes
1 crohn's disease 32.9 TNF NOD2 NLRP3 CXCL8
2 colitis 31.9 TNF NOD2 IL1R1 CXCL8
3 crohn's colitis 31.5 TNF NOD2 CXCL8
4 vasculitis 31.4 TNF MEFV ITGB2 IFNA2 APOH
5 myelofibrosis 31.2 TNF IFNA2 CXCL8 CSF3
6 ulcerative colitis 31.1 TNF NOD2 IL1RN IL1R1 CXCL8
7 keratitis, hereditary 31.1 TNF MMP9 CXCL8
8 sclerosing cholangitis 30.8 TNF NOD2 CXCL8
9 skin disease 30.8 TNF SIGLEC5 MMP1 ITGB2 CXCL8
10 antiphospholipid syndrome 30.8 TNF F3 APOH
11 cyclic neutropenia 30.8 TNF CXCL8 CSF3
12 collagenous colitis 30.8 NOD2 MMP9 MMP1
13 necrotizing fasciitis 30.7 IL1RN F3 CXCL8
14 purpura 30.7 TNF MEFV F3 APOH
15 cryoglobulinemia 30.7 TNF IFNA2 APOH
16 hepatitis a 30.6 TNF IFNA2 F3
17 polyarteritis nodosa 30.6 MEFV IFNA2 APOH
18 acute graft versus host disease 30.6 TNF NOD2 CSF3
19 fasciitis 30.5 TNF MMP1 IL1RN CXCL8
20 invasive aspergillosis 30.5 NOD2 CXCL8 CSF3
21 vascular disease 30.4 TNF MMP9 F3 CSF3 APOH
22 lung disease 30.4 TNF MMP9 F3 CXCL8 CSF3
23 spondylitis 30.4 TNF NOD2 IL1RN
24 bacterial pneumonia 30.4 TNF CXCL8 CSF3
25 leprosy 3 30.4 TNF NOD2 CXCL8
26 aortitis 30.3 TNF NOD2 IL1RN
27 endocarditis 30.3 TNF CXCL8 APOH
28 uveitis 30.3 TNF NOD2 IL1R1 IFNA2 CXCL8
29 scleritis 30.2 TNF MMP9 ITGB2 IL1RN
30 pouchitis 30.2 NOD2 IL1RN CXCL8
31 septic arthritis 30.1 MMP10 MMP1 CXCL8
32 neurofibromatosis, type ii 30.1 TNF SIGLEC5 PSTPIP1 MEFV IL1RN CXCL8
33 spondyloarthropathy 1 30.1 TNF NOD2 IL1RN IL1R1
34 juvenile rheumatoid arthritis 30.1 TNF IL1RN IL1R1 CXCL8
35 vaginitis 30.1 TNF SIGLEC5 CXCL8
36 endometritis 30.0 TNF SIGLEC5 CXCL8
37 pustulosis of palm and sole 30.0 TNF SIGLEC5 IL1RN CXCL8
38 peptic ulcer disease 30.0 TNF IL1RN CXCL8
39 varicose veins 30.0 TNF MMP9 MMP1 CXCL8
40 essential thrombocythemia 30.0 TNF IFNA2 F3 CXCL8 CSF3
41 limb ischemia 29.9 TNF SIGLEC5 MMP9
42 psoriatic arthritis 29.9 TNF NOD2 MMP1 IL1RN
43 atrophic gastritis 29.9 TNF IL1RN CXCL8
44 autoimmune disease 29.8 TNF MMP9 IL1RN IL1R1 CXCL8 APOH
45 chronic recurrent multifocal osteomyelitis 29.8 TNF PSTPIP1 NLRP3 MEFV IL1RN
46 toxic shock syndrome 29.8 TNF IL1RN IL1R1 F3 CXCL8
47 osteomyelitis 29.7 TNF NOD2 NLRP3 IL1RN CXCL8 CSF3
48 takayasu arteritis 29.6 TNF MMP9 IL1RN F3 APOH
49 aspergillosis 29.6 TNF NOD2 IL1RN IL1R1 CXCL8 CSF3
50 pericarditis 29.6 TNF MEFV IL1RN CXCL8

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to Pyoderma Gangrenosum

Symptoms & Phenotypes for Pyoderma Gangrenosum

Human phenotypes related to Pyoderma Gangrenosum:

58 31 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 arthralgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002829
3 papule 58 31 hallmark (90%) Very frequent (99-80%) HP:0200034
4 skin ulcer 58 31 hallmark (90%) Very frequent (99-80%) HP:0200042
5 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
6 myositis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100614
7 myelodysplasia 58 31 frequent (33%) Frequent (79-30%) HP:0002863
8 inflammation of the large intestine 58 31 frequent (33%) Frequent (79-30%) HP:0002037
9 increased antibody level in blood 58 31 frequent (33%) Frequent (79-30%) HP:0010702
10 rheumatoid arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001370
11 pustule 58 31 frequent (33%) Frequent (79-30%) HP:0200039
12 atrophic scars 58 31 frequent (33%) Frequent (79-30%) HP:0001075
13 myeloid leukemia 58 31 frequent (33%) Frequent (79-30%) HP:0012324
14 abnormal blistering of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0008066
15 skin vesicle 58 31 occasional (7.5%) Occasional (29-5%) HP:0200037

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CSF3 F3 IL1R1 IL1RN ITGB2 MEFV
2 immune system MP:0005387 9.77 CSF3 F3 IL1R1 IL1RN ITGB2 MEFV
3 integument MP:0010771 9.28 CSF3 F3 IL1R1 IL1RN ITGB2 MEFV

Drugs & Therapeutics for Pyoderma Gangrenosum

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
2
Adalimumab Approved Phase 2, Phase 3 331731-18-1 16219006
3 Anti-Bacterial Agents Phase 3
4 Anti-Infective Agents Phase 3
5 Anti-Inflammatory Agents Phase 2, Phase 3
6 Antirheumatic Agents Phase 2, Phase 3
7 Pharmaceutical Solutions Phase 3
8 Ixekizumab Approved, Investigational Phase 2 1143503-69-8
9
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
10 Dermatologic Agents Phase 2
11 Immunosuppressive Agents Phase 2
12 Calcineurin Inhibitors Phase 2
13 Antibodies, Monoclonal Phase 1, Phase 2
14 Immunologic Factors Phase 1, Phase 2
15 Immunoglobulins Phase 1, Phase 2
16 Antibodies Phase 1, Phase 2
17
Infliximab Approved 170277-31-3
18 sodium fluoride Approved 7681-49-4
19 Gastrointestinal Agents
20 Fluorides
21 Listerine

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
2 A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease Completed NCT00445432 Phase 2, Phase 3
3 A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan Active, not recruiting NCT03311464 Phase 3 adalimumab
4 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02326740 Phase 3 gevokizumab;Placebo;gevokizumab open-label
5 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02315417 Phase 3 gevokizumab;Placebo;gevokizumab open-label
6 A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum Terminated NCT02318914 Phase 3 gevokizumab
7 An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum Completed NCT01882504 Phase 2 gevokizumab
8 A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Completed NCT01965613 Phase 2
9 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Completed NCT03137160 Phase 2
10 Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease Completed NCT01233570 Phase 2 Tacrolimus
11 A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum Completed NCT01302795 Phase 2 Canakinumab
12 Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Recruiting NCT02733094 Phase 1, Phase 2 Secukinumab
13 Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum Recruiting NCT03971643 Phase 2 IFX-1
14 A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum Terminated NCT03072953 Phase 2 APD334
15 A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37) Withdrawn NCT00690846 Phase 2 adalimumab
16 Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Withdrawn NCT00730717 Phase 2 Humira;Humira
17 Cutaneous JAK Expression in Vitiligo and Acne Vulgaris. Unknown status NCT03185312
18 An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum Completed NCT00791557 Infliximab
19 Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease Completed NCT00487396
20 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Completed NCT00933296
21 Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses Recruiting NCT01952275
22 A Real World, Observational Registry of Chronic Wounds and Ulcers to Assess Quality of Care, Evidence Based Practice and Outcomes Using Linked Electronic Health Record Data Recruiting NCT02280733
23 Genetics and Pathophysiology of Autoinflammatory Disorders. Recruiting NCT00001373
24 Chronic Recurrent Multifocal Osteomyelitis - Search for a Bacterial Cause and Improving Imaging With PET/MRI Recruiting NCT03433287
25 Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015 Not yet recruiting NCT03636737

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Clofazimine
SULFAPYRIDINE PWDR

Cochrane evidence based reviews: pyoderma gangrenosum

Genetic Tests for Pyoderma Gangrenosum

Anatomical Context for Pyoderma Gangrenosum

MalaCards organs/tissues related to Pyoderma Gangrenosum:

40
Skin, Neutrophil, Breast, T Cells, Myeloid, Lung, Bone

Publications for Pyoderma Gangrenosum

Articles related to Pyoderma Gangrenosum:

(show top 50) (show all 3000)
# Title Authors PMID Year
1
Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene. 54 61
19700023 2009
2
Pyrin Modulates the Intracellular Distribution of PSTPIP1. 54 61
19584923 2009
3
PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. 54 61
19290936 2009
4
The inherited autoinflammatory syndrome: a decade of discovery. 54 61
19768193 2009
5
Autoinflammatory diseases: clinical and genetic advances. 54 61
18347298 2008
6
Autoinflammatory gene mutations in Behçet's disease. 54 61
17213252 2007
7
The systemic autoinflammatory diseases: inborn errors of the innate immune system. 54 61
16724804 2006
8
Autoinflammatory syndromes. 54 61
16466630 2006
9
Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. 54 61
15916580 2005
10
A common pathway in periodic fever syndromes. 54 61
15324736 2004
11
CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease. 54 61
15102098 2004
12
Giant pyoderma gangrenosum in a patient with ulcerative colitis: A case report. 61
32028391 2020
13
Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review. 61
31541746 2020
14
Peristomal ulcers misdiagnosed as pyoderma gangrenosum: a common error. 61
31667908 2020
15
A rare case of Granulomatous Wegener with multiple Pyoderma gangrenosum-like ulcers. 61
32031728 2020
16
Pyoderma gangrenosum at multiple sites in a post-colostomy ulcerative colitis patient with chronic hepatitis B virus: A case report. 61
31663272 2020
17
Paraneoplastic pyoderma gangrenosum in solid organ malignancy: a literature review. 61
31512760 2020
18
Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia. 61
30839345 2020
19
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma. 61
31822948 2020
20
Pyoderma gangrenosum arising on vinorelbine infusion site with additional histopathological features of syringosquamous metaplasia. 61
31951074 2020
21
Pyoderma gangrenosum adverse event with Rituximab use: A postmarketing pharmacovigilance analysis. 61
31925868 2020
22
Rhupus With Pyoderma Gangrenosum Treated With Immunosuppression and Skin Grafting. 61
32000228 2020
23
Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction. 61
31705566 2020
24
Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum. 61
31875484 2020
25
Pyoderma gangrenosum-like lesions provocated by botulinum injections. 61
31957116 2020
26
Perioperative Management of Pyoderma Gangrenosum. 61
31927079 2020
27
Pyoderma gangrenosum underrepresentation in non-dermatological literature. 61
31913849 2020
28
Herpes simplex infection mimicking classical pyoderma gangrenosum. 61
31956978 2020
29
Hemiarthroplasty in a patient with femoral neck fracture and pyoderma gangrenosum: a case report and review of the literature. 61
31931877 2020
30
[Complex treatment of pyoderma gangrenosum after minor trauma and primary surgical intervention with suspected necrotizing fasciitis]. 61
31392345 2020
31
Clinically inactive pyoderma gangrenosum successfully treated with negative pressure therapy and punch grafting. 61
31898868 2020
32
Common and critical inflammatory dermatoses every pathologist should know. 61
31676787 2020
33
[Pyoderma gangrenosum and systemic lupus erythematosus: A rare association]. 61
31495525 2020
34
Association of herpes zoster and chronic inflammatory skin disease in United States inpatients. 61
31958523 2020
35
Current Management of Intestinal Stomas and Their Complications. 61
32002473 2020
36
Pediatric Cullen gangrene: Case report of postoperative pyoderma gangrenosum in a preterm infant with a complex gastrointestinal malformation. 61
31954341 2020
37
Therapeutic Efficacy of the Combination Therapy of Corticosteroids and 5-Aminosalicylic Acid for Treatment of Pyoderma Gangrenosum with Ulcerative Colitis. 61
32029938 2020
38
Drug allergy is associated with the development of extraintestinal manifestations in patients with ulcerative colitis. 61
31594293 2020
39
Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. 61
31925675 2020
40
Black aortic valve: Minocycline pigmentation complicating treatment of pyoderma gangrenosum. 61
31475398 2019
41
The 5 P's of Pyoderma Gangrenosum 61
31860220 2019
42
Necrotising fasciitis or pyoderma gangrenosum: A fatal dilemma. 61
31418533 2019
43
Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients - a retrospective, single institution observation. 61
31310348 2019
44
Psoriasis, arthritis, and pyoderma gangrenosum: an autoinflammatory syndrome or a coincidence? 61
31498876 2019
45
Characterisation and diagnosis of ulcers in inpatient dermatology consultation services: A multi-centre study. 61
31475449 2019
46
Current clinical issue of skin lesions in patients with inflammatory bowel disease. 61
30838512 2019
47
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. 61
31254406 2019
48
Paraneoplastic pyoderma gangrenosum associated with adenocarcinoma of the rectosigmoid junction: a case report. 61
31810486 2019
49
´╗┐The Thin bilateral and bipedicled DIEAP flap for axillary reconstruction in hidradenitis suppurativa. 61
31307106 2019
50
Extensive pyoderma gangrenosum-like lesions revealing a case of hyperzincemia and hypercalprotectinemia: when to suspect it? 61
31789267 2019

Variations for Pyoderma Gangrenosum

Expression for Pyoderma Gangrenosum

Search GEO for disease gene expression data for Pyoderma Gangrenosum.

Pathways for Pyoderma Gangrenosum

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 TNF SIGLEC5 PSTPIP1 NOD2 NLRP3 MMP9
2
Show member pathways
13.07 TNF NOD2 MMP9 MMP1 ITGB2 IL1RN
3
Show member pathways
13.06 TNF NOD2 NLRP3 MMP9 IFNA2 CXCL8
4 12.32 TNF NLRP3 IL1R1 CXCL8
5
Show member pathways
12.26 TNF MMP9 MMP1 CXCL8 CSF3
6 12.23 TNF NLRP3 IL1R1 CXCL8
7 12.17 TNF NOD2 ITGB2 IFNA2
8
Show member pathways
12.14 TNF IL1RN IL1R1 F3 CXCL8
9
Show member pathways
12 TNF MMP9 MMP10 ITGB2
10 11.96 TNF NLRP3 MEFV CXCL8
11 11.96 TNF MMP9 IL1R1 CXCL8
12
Show member pathways
11.93 PSTPIP1 NOD2 NLRP3 MEFV
13 11.87 TNF ITGB2 IL1R1 CXCL8
14 11.82 TNF MMP9 MMP1 ITGB2 CXCL8
15 11.81 TNF MMP1 ITGB2 CXCL8
16
Show member pathways
11.72 TNF MMP9 MMP26 MMP10 MMP1
17 11.69 TNF NLRP3 ITGB2 CXCL8
18 11.68 MMP9 MMP1 CXCL8
19 11.66 TNF MMP9 IL1RN
20
Show member pathways
11.58 TNF MMP9 MMP1 CXCL8
21 11.56 TNF MMP9 CXCL8 CSF3
22 11.55 TNF ITGB2 CXCL8
23 11.52 MMP9 MMP10 MMP1 CXCL8
24 11.47 TNF MMP9 ITGB2
25 11.42 TNF PSTPIP1 NOD2 NLRP3 MEFV IFNA2
26 11.4 TNF ITGB2 CXCL8 CSF3
27 11.39 NOD2 NLRP3 MEFV
28 11.3 MMP9 MMP1 CXCL8
29 11.12 NLRP3 MMP9 IL1R1
30 11.04 TNF IL1RN IL1R1 CXCL8 CSF3

GO Terms for Pyoderma Gangrenosum

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.63 TNF NOD2 ITGB2 IL1R1 F3 APOH
2 extracellular space GO:0005615 9.61 TNF MMP9 MMP10 IL1RN IFNA2 F3
3 extracellular matrix GO:0031012 9.56 MMP9 MMP26 MMP10 MMP1
4 extracellular region GO:0005576 9.47 TNF NLRP3 MMP9 MMP26 MMP10 MMP1

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.01 PSTPIP1 NOD2 NLRP3 MEFV C7
2 immune response GO:0006955 9.91 TNF IL1RN IL1R1 CXCL8 CSF3 C7
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 TNF NOD2 NLRP3 ITGB2
4 negative regulation of inflammatory response GO:0050728 9.8 NLRP3 MVK MMP26 MEFV
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.77 TNF NLRP3 F3
6 positive regulation of JNK cascade GO:0046330 9.77 TNF NOD2 IL1RN
7 defense response GO:0006952 9.77 TNF NOD2 NLRP3 IFNA2 CXCL8
8 neutrophil chemotaxis GO:0030593 9.76 ITGB2 IL1RN CXCL8
9 extracellular matrix disassembly GO:0022617 9.75 MMP9 MMP10 MMP1
10 positive regulation of interleukin-6 production GO:0032755 9.74 TNF NOD2 IL1RN
11 extracellular matrix organization GO:0030198 9.73 TNF MMP9 MMP26 MMP10 MMP1 ITGB2
12 regulation of inflammatory response GO:0050727 9.71 TNF NOD2 NLRP3 IL1R1
13 cellular response to lipopolysaccharide GO:0071222 9.63 TNF NOD2 NLRP3 IL1RN CXCL8 CSF3
14 collagen catabolic process GO:0030574 9.62 MMP9 MMP26 MMP10 MMP1
15 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.61 TNF ITGB2
16 inflammatory response GO:0006954 9.61 TNF PSTPIP1 NLRP3 MEFV ITGB2 IL1RN
17 cellular response to peptidoglycan GO:0071224 9.56 NOD2 NLRP3
18 positive regulation of type 2 immune response GO:0002830 9.55 NOD2 NLRP3
19 cellular extravasation GO:0045123 9.52 TNF ITGB2
20 cytokine secretion involved in immune response GO:0002374 9.51 NOD2 NLRP3
21 positive regulation of prostaglandin-E synthase activity GO:2000363 9.48 NOD2 ITGB2
22 detection of biotic stimulus GO:0009595 9.46 NOD2 NLRP3
23 cytokine-mediated signaling pathway GO:0019221 9.32 TNF MMP9 MMP1 ITGB2 IL1RN IL1R1

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TNF PSTPIP1 NLRP3 MVK MMP9 MEFV
2 metallopeptidase activity GO:0008237 9.46 MMP9 MMP26 MMP10 MMP1
3 metalloendopeptidase activity GO:0004222 9.26 MMP9 MMP26 MMP10 MMP1
4 cytokine activity GO:0005125 9.02 TNF IL1RN IFNA2 CXCL8 CSF3

Sources for Pyoderma Gangrenosum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....